Faculty Articles
Integrase Inhibitors: After 10 Years of Experience, Is the Best Yet to Come?
ISBN or ISSN
1875-9114
Publication Title
Pharmacotherapy
Volume
39
Issue
5
Publication Date / Copyright Date
5-1-2019
First Page
576
Last Page
598
Publisher
Wiley
DOI Number
10.1002/phar.2246
Abstract
The era of the integrase strand transfer inhibitors (INSTIs) for the treatment of human immunodeficiency virus (HIV) infection began with raltegravir in 2007. Since that time, several other INSTIs have been introduced including elvitegravir, dolutegravir, and, most recently, bictegravir, that have shown great utility as part of antiretroviral regimens in both treatment-naive and treatment-experienced patients. At present, antiretroviral guidelines fully endorse the INSTI class as part of all first-line treatment regimens. After 10 years of experience with INSTIs, newer agents are on the horizon such as cabotegravir and MK-2048 for potential use as either HIV pre-exposure prophylaxis or maintenance therapy. This review provides a brief overview of the INSTI class including agents currently available and those still in development, reviews available data from both completed and ongoing clinical trials, and outlines simplification strategies using INSTIs.
Disciplines
Medicine and Health Sciences | Pharmacy and Pharmaceutical Sciences
Keywords
antiretroviral therapy, HIV, Integrase inhibitors
NSUWorks Citation
Brooks, Kristina M.; Sherman, Elizabeth M.; Egelund, Eric F.; Brotherton, Amy; Durham, Spencer; Badowski, Melissa E.; and Cluck, David B., "Integrase Inhibitors: After 10 Years of Experience, Is the Best Yet to Come?" (2019). Faculty Articles. 363.
https://nsuworks.nova.edu/hpd_corx_facarticles/363
